TY -的T1短treatm投资一个小说ent regimen for multidrug-resistant tuberculosis: to be repeated JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00081-2017 VL - 49 IS - 3 SP - 1700081 AU - Yassin, Mohammed A. AU - Jaramillo, Ernesto AU - Wandwalo, Eliud AU - Falzon, Dennis AU - Scardigli, Anna AU - Kunii, Osamu AU - Weyer, Karin Y1 - 2017/03/01 UR - //www.qdcxjkg.com/content/49/3/1700081.abstract N2 - Tuberculosis (TB) patients with multidrug-resistant (resistance to isoniazid and rifampicin) (MDR-TB) or rifampicin-resistant strains (MDR/RR-TB) do not respond to the standardised first-line TB regimen which is highly effective in other TB patients, requiring much longer and toxic second-line treatment [1]. In fact, only about a half of all MDR/RR-TB patients placed on these regimens worldwide complete them successfully, attesting to the difficulties in scaling up such regimens satisfactorily [2]. Even if only about 4% of new TB patients globally have MDR/RR-TB, they account for over half a million new individuals annually, challenging the constrained resources available for TB care in the low- and middle-income countries where most of them live.Donor support of innovative interventions such as operational research can reap rapid benefits for TB control http://ow.ly/wcXM3091P9HAuthors’ contributions: all authors contributed substantively to the ideation and writing of the manuscript and approved its final version. M.A. Yassin, E. Wandwalo, A. Scardigli and O. Kunii are staff members of the Global Fund to Fight AIDS, Tuberculosis and Malaria. D. Falzon, E. Jaramillo and K. Weyer are staff members of the World Health Organization. The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions or policies of WHO and the Global Fund. ER -